Adial Pharmaceuticals (ADIL) Expected to Announce Quarterly Earnings on Wednesday

Adial Pharmaceuticals (NASDAQ:ADIL) will likely be announcing its Q3 2026 results on Wednesday, November 18th. Analysts expect the company to post earnings of ($0.1750) per share for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Adial Pharmaceuticals (NASDAQ:ADIL) last posted its quarterly earnings data on Friday, August 14th. The company reported ($11.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.03) by ($10.22).

Adial Pharmaceuticals Stock Down 3.4%

ADIL opened at $4.88 on Wednesday. The business has a fifty day moving average of $4.58 and a 200 day moving average of $3.24. The stock has a market cap of $12.80 million, a P/E ratio of -0.33 and a beta of 1.50. Adial Pharmaceuticals has a 52-week low of $1.31 and a 52-week high of $9.30.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Wall Street Zen upgraded Adial Pharmaceuticals to a “sell” rating in a research report on Saturday, August 15th. Alliance Global Partners assumed coverage on shares of Adial Pharmaceuticals in a research note on Monday, August 3rd. They set a “buy” rating and a $11.00 target price for the company. Finally, Weiss Ratings upgraded shares of Adial Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, October 28th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Adial Pharmaceuticals has an average rating of “Hold” and a consensus price target of $8.33.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for addiction and related disorders. The company’s primary product candidate is AD04, an investigational formulation of ondansetron, a serotonin 5-HT3 receptor antagonist, being developed as a pharmacogenetically targeted treatment for alcohol use disorder. AD04 is designed for people with alcohol use disorder who have specific genetic characteristics that may influence treatment response. Adial’s development approach combines pharmaceutical treatment with genetic testing to identify potentially responsive patient populations.